Nelly Group Past Earnings Performance
Past criteria checks 3/6
Nelly Group has been growing earnings at an average annual rate of 22.5%, while the Specialty Retail industry saw earnings growing at 0.1% annually. Revenues have been declining at an average rate of 16.9% per year. Nelly Group's return on equity is 17.8%, and it has net margins of 3%.
Key information
22.5%
Earnings growth rate
27.4%
EPS growth rate
| Specialty Retail Industry Growth | 4.1% |
| Revenue growth rate | -16.9% |
| Return on equity | 17.8% |
| Net Margin | 3.0% |
| Next Earnings Update | 12 Jul 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Nelly Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,049 | 31 | 473 | 0 |
| 31 Dec 23 | 1,061 | -1 | 495 | 0 |
| 30 Sep 23 | 1,146 | -29 | 531 | 0 |
| 30 Jun 23 | 1,194 | -54 | 554 | 0 |
| 31 Mar 23 | 1,245 | -78 | 600 | 0 |
| 31 Dec 22 | 1,299 | -72 | 622 | 0 |
| 30 Sep 22 | 1,319 | -72 | 642 | 0 |
| 30 Jun 22 | 1,347 | -86 | 683 | 0 |
| 31 Mar 22 | 1,405 | -59 | 679 | 0 |
| 31 Dec 21 | 1,428 | -48 | 679 | 0 |
| 30 Sep 21 | 1,415 | -32 | 671 | 0 |
| 30 Jun 21 | 1,409 | -22 | 645 | 0 |
| 31 Mar 21 | 1,403 | -42 | 648 | 0 |
| 31 Dec 20 | 1,394 | -71 | 663 | 0 |
| 30 Sep 20 | 710 | -105 | 462 | 0 |
| 30 Jun 20 | 945 | -100 | 448 | 0 |
| 31 Mar 20 | 1,102 | -89 | 368 | 0 |
| 31 Dec 19 | 1,452 | -87 | 407 | 0 |
| 30 Sep 19 | 2,812 | -55 | 791 | 0 |
| 30 Jun 19 | 2,936 | -46 | 788 | 0 |
| 31 Mar 19 | 3,195 | -132 | 854 | 0 |
| 31 Dec 18 | 3,258 | -136 | 797 | 0 |
| 30 Sep 18 | 3,388 | -97 | 626 | 0 |
| 30 Jun 18 | 3,409 | -97 | 638 | 0 |
| 31 Mar 18 | 3,408 | -5 | 623 | 0 |
| 31 Dec 17 | 3,397 | 29 | 600 | 0 |
| 30 Sep 17 | 2,693 | -14 | 485 | 0 |
| 30 Jun 17 | 2,830 | -35 | 498 | 0 |
| 31 Mar 17 | 2,943 | -40 | 496 | 0 |
| 31 Dec 16 | 3,159 | -49 | 533 | 0 |
| 30 Sep 16 | 4,150 | -81 | 692 | 0 |
| 30 Jun 16 | 4,257 | -86 | 694 | 0 |
| 31 Mar 16 | 4,327 | -96 | 712 | 0 |
| 31 Dec 15 | 4,431 | -102 | 712 | 0 |
| 30 Sep 15 | 4,593 | -80 | 683 | 0 |
| 30 Jun 15 | 4,784 | -52 | 679 | 0 |
| 31 Mar 15 | 4,906 | -23 | 699 | 0 |
| 31 Dec 14 | 5,015 | 3 | 706 | 0 |
| 30 Sep 14 | 4,836 | 26 | 690 | 0 |
| 30 Jun 14 | 4,664 | 9 | 675 | 0 |
| 31 Mar 14 | 4,523 | -54 | 650 | 0 |
| 31 Dec 13 | 4,441 | -67 | 637 | 0 |
| 30 Sep 13 | 4,543 | -174 | 652 | 0 |
| 30 Jun 13 | 4,576 | -163 | 655 | 0 |
Quality Earnings: CD20 has high quality earnings.
Growing Profit Margin: CD20 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CD20 has become profitable over the past 5 years, growing earnings by 22.5% per year.
Accelerating Growth: CD20 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CD20 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Specialty Retail industry (-15.3%).
Return on Equity
High ROE: CD20's Return on Equity (17.8%) is considered low.